Who owns Atea Pharmaceuticals, Inc. (ALNAQ)? Elite investor 13F holders
2 tracked elite investors reported holding Atea Pharmaceuticals, Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | ATEA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 5260080.00 USD | 1131200.000000 | Shares | reduce | Original filing |
| D.E. Shaw | ATEA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1605115.00 USD | 345186.000000 | Shares | reduce | Original filing |
| Irenic Capital | ATEA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.